Our present results suggested that repression of KLF5 promoted olaparib-induced DNA damage in pancreatic cancer cells and increased olaparib sensitivity by suppressing the transcription of BRCA1, which could be reversed by upregulation of BRCA1. This evidence concerns the gene KLF5 and pancreatic neoplasm.